Dr Lindsay Rosenwald | Lindsay Rosenwald Success & Achievements

As is among the most respected business people within the field of biotechnology, Dr. Lindsay Rosenwald’s countless contributions to that industry is as the Founder and Chairman of a Group of Companies. These kinds of projects consist of a company that helps to facilitate and synchronize drug development and corporate development pursuits, a global pharmaceutical drug development and health care investment organization specializing in the conception, nurturing, and assistance of new biotechnology firms. Also boosting its numerous portfolio companies is a listed broker-dealer with Financial Industry Regulatory Authority, Inc., or FINRA.

After graduating from Abington High School in southeastern Pennsylvania in 1973, Dr. Rosenwald went to Pennsylvania State University as a Finance major. He graduated as a member of Beta Gamma Sigma, an extremely regarded and acclaimed honor society, then proceeded to study at Temple University’s School of Medicine. After completing his studies at Temple, Dr. Rosenwald went into private practice where he continued until 1986. At that time, he relocated to Wall Street to serve as a physician/financial expert, a specialized mixture of career fields that not many boasted at that time.

Dr. Lindsay Rosenwald has revolutionized the field of bioresearch and biotechnology. One of his portfolio firms hold the record for a drug, Arsenic Trioxide, moving most quickly from development to Food & Drug Administration acceptance. Yet another of his firms, Cougar Biotechnology, was bought by J&J in 2009 mainly due to their work with abiraterone acetate. This drug wasn’t yet in stage III medical tests for its application in the management of prostate cancer but was so promising that Johnson & Johnson purchased the company in a “short-term merger” for around $1 billion. It’s intriguing to take note, Abiraterone acetate is founded on Traditional Chinese Medicine practices. Aside from providing initial funds to a lot of of today’s most notable bio-tech companies, Dr. Rosenwald also supports many charities and institutions though the Rosenwald Foundation, of which he’s the chairman. His generous gifts provide the means for scientists to develop the medications for the future.

With all of his different knowledge and qualifications, Dr. Rosenwald leads the world in cutting edge research and development in the bio-tech field. It is because of his special combination of education and knowledge in the finance and bio-tech world that he can incorporate experiences from both fields and build distinctive new experiences. There are very few people on the globe that can match Dr. Rosenwald’s impressive achievements in such a highly specialized field.

Dr. Lindsay Rosenwald, does work with that unit of businesses which is mostly connected with investment money managing, asset supervision, plus direct investing and venture capital in the life-science and biotechnological business. One organization utilizes a amalgamation of U.S. based and also foreign hedge funds and also private equity for the purpose of managing their investor assets. In addition to that Dr. Lindsay Rosenwald possesses an association with the Managing Member of Orion Biomedical Fund, LP and the Orion Biomedical Offshore Fund, LP. Both of these organizations are helping in Financing. Over the course of more than 20 years, Dr. Lindsay Rosenwald has collaborated as a Wall Street entrepreneur in biotechnology. He has initiated and re-capitalized many private and public life-sciences and biotechnology businesses. The portfolio establishments have so far crafted three new chemical agents that have been permitted by the FDA and they at the current moment have a large number of compounds that are even still undergoing clinical trials. One such portfolio company named PolaRx BioPharmaceuticals, Inc., has been granted a final marketing endorsement for a leukemia product recognized as arsenic trioxide. This was concluded only 30 months, an industry highest achievement, after the therapy of the very first testees was finished in a corporate clinical assessment. 5 Other than Cougar Biotechnology, Dr. Lindsay Rosenwald has additionally taken it upon himself to either pay for or originate such companies as Bradley Pharmaceuticals, Inc., Repligen Corporation, Avigen, Inc., Cardiome Pharma Corp., Neose Technologies Inc., Biocryst Pharmaceuticals, Inc, Cypress Bioscience, Inc., Genta, Inc, Discovery Laboratories, Inc., Indevus Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Cell Therapeutics, Inc., and Hudson Health Sciences, Inc.

In relation to his educational background, Dr. Lindsay Rosenwald was a graduate of Abington High School, in the southeast area of Pennsylvania, back in 1973. The future business man and doctor proceeded to graduate Beta Gamma Sigma with a degree in Finance and Economy from Pennsylvania State University in 1977. Afterwards, he discovered employment as an independent management consultant, laboring for various health care businesses during the years 1977 to 1979 and then entering himself into the Temple University School of Medicine. He graduated from Temple in 1983 and soon following began an internship at the Abington Medical Hospital, staying in the private medicine industry until the year 1986. Dr. Lindsay Rosenwald then moved on to Wall Street in order to mix his economic and medical skills and operate as a medical doctor/financial analyst.

Lindsay Rosenwald and His Career

Dr. Lindsay A. Rosenwald asserted himself as a corporate finance managing director for D.H. Blair & Company, in the year of 1988. This was a non public investment based business. There, he operated as the supervisor of a team of three doctor-financiers that sought through the health community for any new and profit-making advancements that could make use of private investment. They succeeded in finding various medical schools, universities, hospitals, pharmaceutical companies, study groups, and scientific firms.  Here, he worked within the biotechnology and bioresearch fields. He became a NASD-member dealer in 1992 and founded the investment and commercial bank. Owned by Dr. Lindsay A. Rosenwald, the Capital Asset Management company has directed investments from quite a few funds since 1994 that have a concentration in the biotechnology and other technological arenas. Dr. Rosenwald is a member of the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires having a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He resigned in order to grant additional time laboring in the biotechnology area. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another business that was originally founded by Dr. Rosenwald and was established exclusively on abiraterone acetate. Abiraterone Acetate, even though it had not yet arrived at phase III in clinical testing trials, was demonstrating so much potential in the therapy and handling for prostate cancer that Johnson & Johnson permitted a short-term merger bid and procurement  for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the various ventures which have bestowed funding and assets to portfolio companies, has also established the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in offering millions of dollars in aid of countless medical and scientific instruction institutions.